Winton Group’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$428K Sell
3,403
-4,254
-56% -$535K 0.02% 626
2025
Q1
$847K Buy
7,657
+136
+2% +$15K 0.05% 453
2024
Q4
$1.03M Buy
+7,521
New +$1.03M 0.07% 352
2024
Q3
Sell
-10,689
Closed -$1.47M 726
2024
Q2
$1.47M Buy
+10,689
New +$1.47M 0.1% 151
2024
Q1
Sell
-4,155
Closed -$547K 784
2023
Q4
$547K Sell
4,155
-117
-3% -$15.4K 0.04% 237
2023
Q3
$481K Buy
4,272
+1,738
+69% +$196K 0.04% 260
2023
Q2
$239K Sell
2,534
-39,708
-94% -$3.74M 0.02% 610
2023
Q1
$4.28M Buy
42,242
+12,542
+42% +$1.27M 0.26% 56
2022
Q4
$3.55M Sell
29,700
-16,429
-36% -$1.96M 0.23% 72
2022
Q3
$4.9M Buy
46,129
+2,849
+7% +$303K 0.32% 48
2022
Q2
$4.22M Buy
43,280
+6,773
+19% +$660K 0.22% 92
2022
Q1
$3.42M Sell
36,507
-3,954
-10% -$371K 0.18% 110
2021
Q4
$3.45M Buy
40,461
+19,957
+97% +$1.7M 0.21% 86
2021
Q3
$1.97M Sell
20,504
-1,283
-6% -$123K 0.11% 185
2021
Q2
$2.12M Sell
21,787
-955
-4% -$92.9K 0.11% 165
2021
Q1
$2.21M Buy
22,742
+1,165
+5% +$113K 0.13% 119
2020
Q4
$2.07M Sell
21,577
-42,075
-66% -$4.03M 0.15% 97
2020
Q3
$6.12M Buy
63,652
+8,149
+15% +$784K 0.2% 82
2020
Q2
$6.77M Buy
55,503
+14,363
+35% +$1.75M 0.17% 116
2020
Q1
$3.56M Buy
41,140
+7,496
+22% +$649K 0.09% 378
2019
Q4
$3.62M Buy
33,644
+20,505
+156% +$2.2M 0.05% 584
2019
Q3
$1.18M Buy
+13,139
New +$1.18M 0.01% 760
2019
Q2
Sell
-4,471
Closed -$394K 1238
2019
Q1
$394K Sell
4,471
-1,367
-23% -$120K 0.01% 684
2018
Q4
$417K Sell
5,838
-226
-4% -$16.1K 0.01% 546
2018
Q3
$746K Sell
6,064
-54
-0.9% -$6.64K 0.02% 470
2018
Q2
$601K Sell
6,118
-3,358
-35% -$330K 0.02% 581
2018
Q1
$786K Buy
+9,476
New +$786K 0.02% 590